Bone Accretion in Adolescents Using the Combined Estrogen and Progestin Transdermal Contraceptive Method Ortho Evra: A Pilot Study

Harel, Zeev; Riggs, Suzanne; Vaz, Rosalind; Flanagan, Patricia; Harel, Dalia; Machan, Jason T.

doi:10.1016/j.jpag.2009.04.008

Cited by 23 publications

(11 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Harel et al have also reported inadequate vitamin D levels in adolescents receiving DMPA. 14,15 As those tested in our sample were all at least insufficient, it raises concern and suggests the importance of monitoring vitamin D status during DMPA use. To optimize bone health during DMPA use as a measure to minimize bone loss and reduce fracture risk, vitamin D status must be considered.…”

Section: Discussionmentioning

confidence: 86%

Bone Mineral Density, Fracture, and Vitamin D in Adolescents and Young Women Using Depot Medroxyprogesterone Acetate

Pitts

Feldman

Dorale

et al. 2012

Journal of Pediatric and Adolescent Gynecology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 86%

Bone Mineral Density, Fracture, and Vitamin D in Adolescents and Young Women Using Depot Medroxyprogesterone Acetate

Pitts

Feldman

Dorale

et al. 2012

Journal of Pediatric and Adolescent Gynecology

View full text Add to dashboard Cite

“…185,186 Investigations into the patch' s effect on bone health have yielded inconsistent results, with findings in adults 150,151 more reassuring than those in adolescents. 187 However, this limited work is far from conclusive.…”

Section: Pediatrics Volume 134 Number 4 October 2014 E1267mentioning

confidence: 99%

Contraception for Adolescents

Ott

Sucato²

2014

Pediatrics

245

133

View full text Add to dashboard Cite

A working knowledge of contraception will assist the pediatrician in both sexual health promotion as well as treatment of common adolescent gynecologic problems. Best practices in adolescent anticipatory guidance and screening include a sexual health history, screening for pregnancy and sexually transmitted infections, counseling, and if indicated, providing access to contraceptives. Pediatricians’ long-term relationships with adolescents and families allow them to help promote healthy sexual decision-making, including abstinence and contraceptive use. Additionally, medical indications for contraception, such as acne, dysmenorrhea, and heavy menstrual bleeding, are frequently uncovered during adolescent visits. This technical report provides an evidence base for the accompanying policy statement and addresses key aspects of adolescent contraceptive use, including the following: (1) sexual history taking, confidentiality, and counseling; (2) adolescent data on the use and side effects of newer contraceptive methods; (3) new data on older contraceptive methods; and (4) evidence supporting the use of contraceptives in adolescent patients with complex medical conditions.

show abstract

“…There was a trend towards a greater percent increase in BMD at the hip and spine in nonusers. However, after adjustment, this difference did not achieve statistical significance [92].…”

Section: Other Combination Hormonal Contraceptives (Transdermal Patchmentioning

confidence: 87%

“…In a pilot study, Harel et al examined the effect of one year of use of the transdermal patch on BMD in 10 adolescents 12-21 years of age: 5 patch users and 5 age and ethnicity matched teens not using hormonal contraception [92]. The percent increase in whole body bone mineral content at one year was statistically significantly greater in non-user subjects than in patch users (adjusted p=0.36).…”

Section: Other Combination Hormonal Contraceptives (Transdermal Patchmentioning

confidence: 99%

Update on hormonal contraception and bone density

Isley

Kaunitz

2011

Rev Endocr Metab Disord

View full text Add to dashboard Cite

Combination hormonal contraception and progestin-only contraception (including depot medroxyprogesterone acetate [DMPA]) are effective and convenient forms of reversible contraception that millions of women use worldwide. In recent years, observations of reduced bone mineral density in current users of these methods have led to concerns that this hormone-induced bone loss might translate into long-term increased fracture risk. Special focus has been placed on adolescent users who have not yet attained their peak bone mass as well as perimenopausal users. In 2004, the FDA added a black box warning to DMPA package labeling warning of the risk of significant bone loss and cautioning against long-term use (> 2 years). This article reviews evidence on the use of hormonal contraception and its effect on bone density in adolescent, premenopausal, and perimenopausal populations. Recommendations from reproductive healthcare organizations are reviewed and clinical recommendations are provided.

show abstract

Bone Accretion in Adolescents Using the Combined Estrogen and Progestin Transdermal Contraceptive Method Ortho Evra: A Pilot Study

Cited by 23 publications

References 41 publications

Bone Mineral Density, Fracture, and Vitamin D in Adolescents and Young Women Using Depot Medroxyprogesterone Acetate

Bone Mineral Density, Fracture, and Vitamin D in Adolescents and Young Women Using Depot Medroxyprogesterone Acetate

Contraception for Adolescents

Update on hormonal contraception and bone density

Contact Info

Product

Resources

About